New Partnership Aims to Reshape Inhaled and Nasal Drug Development

CRANBURY, NJ – March 24, 2026 – A new strategic collaboration between contract development and manufacturing organization (CDMO) Experic and formulation specialist Flurry Powders, LLC, is set to accelerate the development of next-generation inhaled and nasal drug products. The partnership integrates Flurry's specialized research and development in spray-dried powders with Experic's clinical and commercial-scale manufacturing capabilities, creating a streamlined pathway for bringing complex new therapies to the clinic.

This alliance arrives at a critical time for the pharmaceutical industry. The global market for inhaled and nasal drug delivery is on a significant upward trajectory, with some market segments projected to grow at a compound annual growth rate of over 7%. This expansion is fueled by a rising prevalence of chronic respiratory diseases like asthma and COPD, coupled with a growing patient and provider preference for non-invasive drug administration. The nasal and pulmonary routes offer rapid onset of action and the ability to deliver drugs directly to the site of action or systemically, bypassing the digestive system and first-pass metabolism in the liver. These advantages are driving innovation beyond traditional respiratory ailments into new frontiers like neurology, vaccines, and biologics.

A Total Systems Approach to Particle Engineering

The collaboration is built on what the companies describe as a “total systems approach,” an end-to-end ecosystem designed to de-risk and expedite the complex journey from lab to clinic. Under the agreement, Flurry Powders will provide Experic's clients with its deep expertise in formulation development, particle engineering, and specialized analytical testing. This synergy addresses a common bottleneck in pharmaceutical development: the difficult transition of a promising drug formulation from small-scale R&D to compliant, large-scale Good Manufacturing Practice (GMP) production.

A central component of this advantage is a unique technological alignment. Experic operates the only GMP-certified spray dryer in the industry that is configured to Flurry Powders' proprietary PSD-1 specifications. This bespoke system has demonstrated the ability to increase the dose of drug delivered to the lung by 15–20% compared to conventional dryers of a similar scale. Spray drying is a sophisticated process that transforms a liquid drug solution into a precisely engineered powder. By controlling particle size, shape, and density, developers can optimize how a powder aerosolizes and travels into the respiratory tract, ensuring the medicine reaches its target effectively.

“Experic’s spray-drying capabilities, aligned with our PSD-1 system, create a seamless bridge from R&D to clinical manufacturing,” said Andreas Boeckl, Founder and CEO of Flurry Powders, in a statement. “Together, we enable innovators to advance complex inhalation and nasal products with greater confidence and performance.”

Unlocking Therapies for Challenging Molecules

The partnership is poised to make its most significant impact on drug candidates that have historically been difficult to formulate. The industry pipeline is increasingly filled with challenging molecules, including lipophilic (fat-soluble), waxy, or poorly water-soluble compounds that resist traditional delivery methods. Furthermore, the development of sensitive biologics—large, complex molecules like proteins, peptides, and RNA-based therapeutics—has been largely confined to injections due to their fragility.

Advanced spray drying offers a solution by stabilizing these delicate molecules within a dry powder matrix, protecting their structure and function. This opens the door for non-invasive delivery of biologics, a major step forward in patient care and compliance. The collaboration enables the development of therapies for a wide array of conditions, moving beyond the traditional confines of respiratory disease. Potential applications include delivering drugs directly to the brain via the nasal passage for treating central nervous system disorders like Alzheimer's or Parkinson's disease, developing needle-free intranasal vaccines, and creating inhaled treatments for oncology and rare genetic disorders.

Reshaping the Competitive CDMO Landscape

In the highly competitive and specialized CDMO market for inhalation products, this alliance positions Experic as a uniquely integrated partner for pharmaceutical innovators. While larger CDMOs like Catalent and Lonza offer extensive spray-drying services, the exclusive alignment between Experic’s GMP manufacturing hardware and Flurry’s proprietary R&D process creates a distinct, high-performance channel. This integrated model is designed to reduce the risks associated with technology transfer and scale-up, which can often lead to costly delays and performance degradation of the final product.

By providing a seamless link between formulation, device selection, aerosol performance characterization, and GMP-aligned manufacturing, the partnership aims to offer a more efficient and predictable path to regulatory submission and clinical trials.

“Partnering with Flurry Powders expands the solutions we offer developers advancing inhaled and nasal therapies,” stated Matthew Mollan, CEO of Experic. “By integrating spray-drying innovation with GMP manufacturing, we enable clients to reduce risk, accelerate timelines, and bring high-performing powder-based products into the clinic.” This strategic move not only enhances Experic's service portfolio but also signals a broader industry trend toward deeper, more specialized collaborations to solve the most pressing challenges in drug delivery.